TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03897491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-aminolevulinic acid
Description: 5-aminolevulinic acid powder for oral solution
Study: NCT05454332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Early Caffeine administration
Description: Blinding will be done with the administration of saline solution. Patients in the early caffeine group will receive an attack dose of caffeine 20 mg/kg and begin maintenance dose 10 mg/kg/day. Patients in the late caffeine group, receive bolus of saline solution in the first 2 hours of life, starting, at 24 hours of life, the caffeine-loading dose 20 mg/kg and after maintenance dose 10mg/kg/day. The medical team will prescribe the medication, and the pharmacy will be responsible for randomly dispensing the caffeine or saline solution. The pharmacy will prepare syringes with the medication or saline solution identified by a code referring to the randomization without identifying which solution is being administered. The syringes will be sent to the neonatal ICU and will be administered according to the physician's prescription. The administration will be blinded.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Blinding will be done with the administration of saline solution. Patients in the early caffeine group will receive an attack dose of caffeine 20 mg/kg and begin maintenance dose 10 mg/kg/day. Patients in the late caffeine group, receive bolus of saline solution in the first 2 hours of life, starting, at 24 hours of life, the caffeine-loading dose 20 mg/kg and after maintenance dose 10mg/kg/day. The medical team will prescribe the medication, and the pharmacy will be responsible for randomly dispensing the caffeine or saline solution. The pharmacy will prepare syringes with the medication or saline solution identified by a code referring to the randomization without identifying which solution is being administered. The syringes will be sent to the neonatal ICU and will be administered according to the physician's prescription. The administration will be blinded.
Study: NCT06500910

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Exercise
Description: 10 weeks of child-friendly physical exercise program
Study: NCT05536869

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Caesarean
Description: Two different caesarean section techniques : intra or extraperitoneal
Study: NCT06268561

Intervention type: OTHER
Intervention: Analysis of retinograms
Description: Collection and analysis of retinography images of the medical file concerning the surgery
Study: NCT05536869

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Caesarean
Description: Two different caesarean section techniques : intra or extraperitoneal
Study: NCT05264545

Intervention type: DEVICE
Group type: OTHER
Intervention: PrimeTaper EV
Description: The PrimeTaper EV Implant is a screw shaped dental implant with a defined surface achieved through grit blasting, followed by a process involving a treatment in diluted hydrofluoric acid. There is a conical connection between the implants and the abutments for a tight and stable connection.
Study: NCT04934046

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Additional acquisition
Description: Additional SPECT acquisition (30min added time approximately), with no added radiation
Study: NCT05740618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mannitol Inhalant Product
Description: A sugar alcohol indicated as an add-on maintenance therapy to improve pulmonary function in adult patients 18 years of age and older with cystic fibrosis.
Study: NCT05378555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine Hydrochloride
Description: All patients in this study will receive oral ketamine for the treatment of pain from vaso-occlusive crisis. Patients will receive 0.5 mg/kg ketamine Q8hrs for 48 hours.
Study: NCT06318312

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypoxia
Description: Hypoxic exposure: FiO2 = 11% Hypoxic exposure: FiO2 = 13% Hypoxic exposure: FiO2 = 15% Hypoxic exposure / placebo: FiO2 = 21%

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypoxia
Description: Hypoxic exposure: FiO2 = 11% Hypoxic exposure: FiO2 = 13% Hypoxic exposure: FiO2 = 15% Hypoxic exposure / placebo: FiO2 = 21%

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypoxia
Description: Hypoxic exposure: FiO2 = 11% Hypoxic exposure: FiO2 = 13% Hypoxic exposure: FiO2 = 15% Hypoxic exposure / placebo: FiO2 = 21%

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Hypoxia
Description: Hypoxic exposure: FiO2 = 11% Hypoxic exposure: FiO2 = 13% Hypoxic exposure: FiO2 = 15% Hypoxic exposure / placebo: FiO2 = 21%
Study: NCT06455397

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Building Emotional Awareness and Mental Health (BEAM) Program
Description: The BEAM Program builds on mHealth best practices and evidence-based program design principles with the core objectives of improving maternal mental health and fostering supportive parenting. Program content draws on transdiagnostic emotion-focused mental health and third wave Cognitive Behavioural Therapy principles such as Dialectical Behavioural Therapy, Acceptance and Commitment Therapy, and the Unified Protocol.~Program delivery will be facilitated through a mobile application. The BEAM program uses a stepped care model to address the pressing need for accessible and effective mental health interventions. Stepped care is a framework that provides mental health services in a tiered manner, ensuring that participants receive appropriate levels of support based on the severity of needs. At the heart of this model are BEAM peer coaches, who will have the most direct contact with participants. Peer coaches are trained to escalate concerns to the program clinical team as required.
Study: NCT06362434

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Audiovisual stimulation
Description: The MOT IVR audiovisual stimulation task involves the 3D multiple-object-tracking paradigm composed of 6-8 high-contrast spheres which features are adapted to the visual ability of individuals with low-vision (luminosity = 80 nits, size = 1° to 3° visual angle). The spheres move for 20s. following random linear paths, bouncing on one another and on the walls of a virtual 3D cube when collisions occur. The participant, comfortably seated, is asked to track the moving cued target among moving distractors for 20s. A spatial sound is correlated to the movement of the cued target. After 20s., the movement stops and the participant is asked to select, using a laser pointer, the cued sphere among the distractors (mark-all procedure). Speed of the spheres is regulated by a staircase 1:1 procedure. The stimulation can here be stopped by the participant if required. After 3 blocks of 15x20s., the system stops and goes on stand-by mode until the next session. Data are collected in real time.
Study: NCT05202418

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Biofeedback Enhanced Treatment
Description: The intervention involves biofeedback enhanced cognitive behaviorally based coping skills treatment. Treatment will consist of a 6-visit group intervention conducted online, via Emory zoom. Groups will include 5-8 patients each. Sessions will include brief, daily homework to facilitate mastery that is developmentally tailored to youth (e.g., practice skills with support from phone or tablet apps). Groups will meet approximately every week for 6 weeks. Advanced Ph.D. students in clinical psychology and Principal Investigator will deliver the treatment protocol. Participants will complete questionnaires before and after each session to measure autonomic reactivity, lifetime stress, depression, anxiety in response to stress induction, and coping strategies.
Study: NCT05458661

Intervention type: DEVICE
Group type: OTHER
Intervention: Clinical Prototype BioBase (SN 07 and SN 08)
Description: Scheimpflug- or OCT based corneal tomographers with the ability to measure anterior and posterior corneal curvature maps \>6mm diameter and corneal pachymetry maps \>6mm.
Study: NCT06141837

Intervention type: OTHER
Intervention: Observation
Description: No intervention: observational study
Study: NCT04518254

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Anxiety scale
Description: Spielberger's State Trait Anxiety Inventory (STAI) will be filled by the participants before and after cognitive tasks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Anxiety scale
Description: Spielberger's State Trait Anxiety Inventory (STAI) will be filled by the participants before and after cognitive tasks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electromyography (EMG)
Description: Electromyography measurements will be performed during cognitive tasks.
Study: NCT06137768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-5965
Description: HRS-5965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-5965
Description: HRS-5965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-5965
Description: HRS-5965

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo.
Study: NCT05577949

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structured aerobics exercise
Description: A 12 week structured aerobics exercise program will be offered. The patient has to perform exercise five times a week , 30 minutes a day
Study: NCT04518254

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electromyography (EMG)
Description: Electromyography measurements will be performed during cognitive tasks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electromyography (EMG)
Description: Electromyography measurements will be performed during cognitive tasks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electromyography (EMG)
Description: Electromyography measurements will be performed during cognitive tasks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroencephalography (EEG)
Description: Electroencephalography measurements will be performed during cognitive tasks.
Study: NCT05047575

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: REASSURE
Description: REASSURE utilizes remote patient-reported outcomes assessments to comprehensively assess symptoms, promotes practice change by providing feedback reports to oncologists and engaging primary care providers (PCPs) in survivorship care, and reduces the burden of follow-up by substituting an oncology visit for thriving survivors with reassurance messaging and encouragement to pursue preventive care.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: REASSURE
Description: REASSURE utilizes remote patient-reported outcomes assessments to comprehensively assess symptoms, promotes practice change by providing feedback reports to oncologists and engaging primary care providers (PCPs) in survivorship care, and reduces the burden of follow-up by substituting an oncology visit for thriving survivors with reassurance messaging and encouragement to pursue preventive care.
Study: NCT05589883

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EMPOWER-Latinx
Description: EMPOWER-Latinx will be delivered in Spanish by videoconferencing (i.e., Zoom, WebEx) with a trained study interventionist. Intervention modules will be audio- and video-recorded (videorecording optional).
Study: NCT05524610

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sexual Function Screening Approach
Description: The screening approach will consist of:~1. Standardized use of the PROMIS SexFS Brief in a clinic setting. This tool assesses sexual interest/desire, arousal, discomfort/pain, climax, and satisfaction, among other SD concerns and has comparable sex-specific versions. It has been validated in adult cancer populations.~2. An implementation package to aid in successful implementation. The implementation package will be finalized in the non-trial portion of this study, which will include iterative intervention adaptation. The protocol will be amended as needed to include any relevant updates to the screening approach. Some components may vary per site.
Study: NCT05739890

Intervention type: OTHER
Intervention: Embryo genome sequencing
Description: This project proposes the testing of a cohort of research embryos to establish the key parameters for amplified trophectoderm biopsied embryos using minimum depth required for genome sequencing (\>depth of 30x per base).The remaining embryo tissue will be whole genome sequenced to validate the results of the biopsy.

Intervention type: OTHER
Intervention: Parents genome sequencing
Description: Analysis will be performed using trio testing of each embryo in addition to the DNA from the genetic parent to facilitate the derivation of de novo mutation rate.
Study: NCT06247462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 600 mg
Description: 600 mg of ibuprofen was ingested 12- and 1-hours prior to exercise.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Corn Starch
Description: 600 mg of corn starch (placebo) was ingested 12- and 1-hours prior to exercise.
Study: NCT04518254

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroencephalography (EEG)
Description: Electroencephalography measurements will be performed during cognitive tasks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroencephalography (EEG)
Description: Electroencephalography measurements will be performed during cognitive tasks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroencephalography (EEG)
Description: Electroencephalography measurements will be performed during cognitive tasks.
Study: NCT06547866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zanubrutinib + BGB-11417
Description: The investigational medicinal products (IMP) are Zanubrutinib (BGB- 3111) and BGB-11417.Treatment will be administered for a total of twenty 28 day cycles:~Cycle 1 with zanubrutinib only~Cycle 2 with zanubrutinib plus BGB-11417 ramp-up cycle 2, day 1 : 10mg cycle 2, day 2 : 20 mg cycle 2, day 3 : 40mg cycle 2, day 4-7 : 80md daily cycle 2, day 8 and beyond : 160 mg daily~Cycles 3-20 with zanubrutinib plus BGB-11417 full dose
Study: NCT04566315

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Arteriography knee arteriography
Description: arteriography and an injection of inert microparticles of 75 μm in neovessels
Study: NCT05173649

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Calisthenic Training
Description: Calisthenic Training Performed thrice a week after baseline assessment Standard Physical therapy treatment along with following exercises.~1. Abductor-Adductor leg raise~2. Alternate toe touch~3. Knee Bend~4. Prone leg extension~5. Forward Lunges~6. Toe Raise/ Calf raise Progressive training include following exercises.~1. Leg Lifts 2. Jack Twists 3. Side Lunges 4. Short bridge 5. Calf Raise with weight.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Calisthenic Training
Description: Calisthenic Training Performed thrice a week after baseline assessment Standard Physical therapy treatment along with following exercises.~1. Abductor-Adductor leg raise~2. Alternate toe touch~3. Knee Bend~4. Prone leg extension~5. Forward Lunges~6. Toe Raise/ Calf raise Progressive training include following exercises.~1. Leg Lifts 2. Jack Twists 3. Side Lunges 4. Short bridge 5. Calf Raise with weight.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular Training
Description: Neuromuscular Training Performed thrice a week after baseline assessment Standard Physical therapy treatment along with following exercises.~1. Up and down step exercise in posterior and lateral directions.~2. Walking in anterior and posterior~3. Directions with eyes opened and eyes closed.~4. Walking in lateral direction with eyes opened and eyes closed.~5. Standing on one extremity~6. Inclination in anterior and lateral direction with eyes opened and closed. Progressive training includes following exercises.~1. Up and down on Bosu exercise. 2. Plantar flexion on minitrampoline. 3. Standing on one extremity on Bosu. 4. Standing on one extremity on minitrampoline

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular Training
Description: Neuromuscular Training Performed thrice a week after baseline assessment Standard Physical therapy treatment along with following exercises.~1. Up and down step exercise in posterior and lateral directions.~2. Walking in anterior and posterior~3. Directions with eyes opened and eyes closed.~4. Walking in lateral direction with eyes opened and eyes closed.~5. Standing on one extremity~6. Inclination in anterior and lateral direction with eyes opened and closed. Progressive training includes following exercises.~1. Up and down on Bosu exercise. 2. Plantar flexion on minitrampoline. 3. Standing on one extremity on Bosu. 4. Standing on one extremity on minitrampoline
Study: NCT05980533

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Ultrasound at hospital discharge and at follow up at 7-10 days
Study: NCT04949165

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iron Supplementation
Description: low dose ferrous sulphate (65mg elemental iron) supplements
Study: NCT06064890

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intrathalamic AAV.PGRN administration
Description: One-time MRI-guided stereotaxic infusion of AAV.PGRN into the brain

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intrathalamic AAV.PGRN administration
Description: One-time MRI-guided stereotaxic infusion of AAV.PGRN into the brain

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Intrathalamic AVB-101
Description: AVB-101 is made from an adeno-associated virus, serotype 9 (AAV9). AAVs are small viruses that are naturally occurring and do not cause illness or infection on their own. AVB-101 has been modified to contain a copy of the correct (non-mutated) GRN gene, plus some other genetic material to enable the GRN gene to function inside neurons (cells within the brain). AVB-101 has also been modified so that it cannot divide and make new copies of itself (known as 'replication'), which means that it cannot cause disease or a large immune response in your body.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Intrathalamic AVB-101
Description: AVB-101 is made from an adeno-associated virus, serotype 9 (AAV9). AAVs are small viruses that are naturally occurring and do not cause illness or infection on their own. AVB-101 has been modified to contain a copy of the correct (non-mutated) GRN gene, plus some other genetic material to enable the GRN gene to function inside neurons (cells within the brain). AVB-101 has also been modified so that it cannot divide and make new copies of itself (known as 'replication'), which means that it cannot cause disease or a large immune response in your body.
Study: NCT06472908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine 0.5 mg
Description: Colchicine 0.5 mg, one pill a day, oral intake

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine 0.375 mg
Description: Colchicine 0.375 mg, one pill a day, oral intake

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, one pill a day, oral intake
Study: NCT06214650

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radiofrequency
Description: Experimental group will receive the common exercise program associated with a radiofrequency treatment using INDIBA® (INDIBA Activ 7, Barcelona, INDIBA S.A.) at a frequency of 448 hertz. It will use the capacitive electrode as a method of preparation and vascularization of the superficial tissues and immediately, within the same session, the resistive electrode to stimulate deep tissues. This treatment is based on the protocols established by INDIBA® S.A.~It will consist of one weekly diathermy session of thirty minutes during ten weeks. The use of diathermy will not be interrupted throughout the session.~The common exercise program consist in a ten abdominal exercises (including recti abdominis, transversus and obliques). It will practised at home only just three days at week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Control group will receive a weekly INDIBA® session in the abdominal area with the same protocol as the experimental group in athermic mode (placebo treatment) and the common exercise program. The session will last thirty minutes and will be carried out by the research physiotherapist during ten weeks.
Study: NCT05897996

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: creation of vascular access for hemodialysis
Description: endo-AVfs created with Wavelinq
Study: NCT04796649

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: B-Cure laser pro
Description: The B-Cure laser Pro is a portal, non-invasive, low level laser therapy device, that emits light in the near infrared (808nm) over an area of 1X4.5 cm2 with power output of 250mW, and energy dose of 5J/min.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham
Description: The sham device is externally identical to the B-Cure Pro and emit the same guiding light, but does not emit the therapeutic near infrared rays.
Study: NCT06335979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PIT565
Description: In each cohort, there will be 3 sentinel participants. Additional participants might be added depending on safety and observed biological activity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PIT565
Description: In each cohort, there will be 3 sentinel participants. Additional participants might be added depending on safety and observed biological activity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PIT565
Description: In each cohort, there will be 3 sentinel participants. Additional participants might be added depending on safety and observed biological activity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PIT565
Description: In each cohort, there will be 3 sentinel participants. Additional participants might be added depending on safety and observed biological activity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PIT565
Description: In each cohort, there will be 3 sentinel participants. Additional participants might be added depending on safety and observed biological activity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PIT565
Description: In each cohort, there will be 3 sentinel participants. Additional participants might be added depending on safety and observed biological activity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PIT565
Description: In each cohort, there will be 3 sentinel participants. Additional participants might be added depending on safety and observed biological activity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PIT565
Description: In each cohort, there will be 3 sentinel participants. Additional participants might be added depending on safety and observed biological activity.
Study: NCT05079100

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: postpartum contraception method counselling
Description: It will be face-to-face counseling with females about the use of postpartum contraception methods within 6 weeks postpartum.